Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma

Figure 3

Tumor progression of the local recurrent tumor during tocilizumab treatment. (a) Axial image of the recurrence tumor in the ankle region acquired using T2-weighted MRI at the time of recurrence. (b) Axial image of the recurrence tumor in the ankle region acquired using T2-weighted MRI 2 months after starting on tocilizumab treatment. (c) Axial image of the recurrence tumor in the ankle region acquired using T2-weighted MRI 4 months after the first evaluation. The tumor is indicated by the arrows in red.

(a)

(b)

(c)